Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Stefano Volpetti, Francesco Zaja, Renato FaninDivision of Hematology and Cellular Therapies Unit “Carlo Melzi”, Department of Experimental and Clinical Sciences, University Hospital “Santa Maria della Misericordia”, Udine, ItalyAbstract: Treatment of patients...

Full description

Bibliographic Details
Main Authors: Volpetti S, Zaja F, Fanin R
Format: Article
Language:English
Published: Dove Medical Press 2014-05-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/pixantrone-for-the-treatment-of-adult-patients-with-relapsed-or-refrac-a17058
id doaj-57cbedae514b41369d24481c8ecdb5be
record_format Article
spelling doaj-57cbedae514b41369d24481c8ecdb5be2020-11-24T23:15:00ZengDove Medical PressOncoTargets and Therapy1178-69302014-05-012014default86587217058Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasVolpetti SZaja FFanin R Stefano Volpetti, Francesco Zaja, Renato FaninDivision of Hematology and Cellular Therapies Unit “Carlo Melzi”, Department of Experimental and Clinical Sciences, University Hospital “Santa Maria della Misericordia”, Udine, ItalyAbstract: Treatment of patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma remains an unmet clinical need, and the progressive myocardial toxicity related to cumulative, dose-dependent damage induced by anthracyclines represents a tricky issue in the planning of therapy. Pixantrone is a promising aza-anthracenedione with reduced cardiotoxicity and significant antineoplastic activity, and has been investigated in solid and hematologic tumors in several Phase I, II, and III trials. The aim of this review is to summarize the data reported so far on pixantrone as a salvage therapy in relapsed/refractory non-Hodgkin B-cell lymphoma.Keywords: pixantrone, aggressive non-Hodgkin B-cell lymphoma, relapsed/refractoryhttp://www.dovepress.com/pixantrone-for-the-treatment-of-adult-patients-with-relapsed-or-refrac-a17058
collection DOAJ
language English
format Article
sources DOAJ
author Volpetti S
Zaja F
Fanin R
spellingShingle Volpetti S
Zaja F
Fanin R
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
OncoTargets and Therapy
author_facet Volpetti S
Zaja F
Fanin R
author_sort Volpetti S
title Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
title_short Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
title_full Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
title_fullStr Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
title_full_unstemmed Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
title_sort pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-hodgkin b-cell lymphomas
publisher Dove Medical Press
series OncoTargets and Therapy
issn 1178-6930
publishDate 2014-05-01
description Stefano Volpetti, Francesco Zaja, Renato FaninDivision of Hematology and Cellular Therapies Unit “Carlo Melzi”, Department of Experimental and Clinical Sciences, University Hospital “Santa Maria della Misericordia”, Udine, ItalyAbstract: Treatment of patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma remains an unmet clinical need, and the progressive myocardial toxicity related to cumulative, dose-dependent damage induced by anthracyclines represents a tricky issue in the planning of therapy. Pixantrone is a promising aza-anthracenedione with reduced cardiotoxicity and significant antineoplastic activity, and has been investigated in solid and hematologic tumors in several Phase I, II, and III trials. The aim of this review is to summarize the data reported so far on pixantrone as a salvage therapy in relapsed/refractory non-Hodgkin B-cell lymphoma.Keywords: pixantrone, aggressive non-Hodgkin B-cell lymphoma, relapsed/refractory
url http://www.dovepress.com/pixantrone-for-the-treatment-of-adult-patients-with-relapsed-or-refrac-a17058
work_keys_str_mv AT volpettis pixantroneforthetreatmentofadultpatientswithrelapsedorrefractoryaggressivenonhodgkinbcelllymphomas
AT zajaf pixantroneforthetreatmentofadultpatientswithrelapsedorrefractoryaggressivenonhodgkinbcelllymphomas
AT faninr pixantroneforthetreatmentofadultpatientswithrelapsedorrefractoryaggressivenonhodgkinbcelllymphomas
_version_ 1725592445876436992

Similar Items